Biocept (BIOC) Shares Gap Down to $1.50

Shares of Biocept Inc (NASDAQ:BIOC) gapped down prior to trading on Wednesday . The stock had previously closed at $1.64, but opened at $1.50. Biocept shares last traded at $1.30, with a volume of 8129925 shares changing hands.

Several research firms have weighed in on BIOC. Maxim Group began coverage on Biocept in a report on Tuesday, March 26th. They issued a “buy” rating on the stock. ValuEngine raised Biocept from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Zacks Investment Research raised Biocept from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Wednesday, February 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Biocept currently has a consensus rating of “Buy” and an average price target of $2.13.

The firm has a market cap of $15.47 million, a price-to-earnings ratio of -0.14 and a beta of 2.80. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.72 and a quick ratio of 1.18.

Biocept (NASDAQ:BIOC) last released its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.61) earnings per share for the quarter. Biocept had a negative net margin of 695.85% and a negative return on equity of 338.61%. The business had revenue of $1.02 million during the quarter. As a group, analysts predict that Biocept Inc will post -3.84 earnings per share for the current year.

An institutional investor recently bought a new position in Biocept stock. Dimensional Fund Advisors LP acquired a new position in shares of Biocept Inc (NASDAQ:BIOC) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 39,445 shares of the medical research company’s stock, valued at approximately $108,000. Dimensional Fund Advisors LP owned approximately 1.74% of Biocept as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.95% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Biocept (BIOC) Shares Gap Down to $1.50” was first published by WKRB News and is owned by of WKRB News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2019/05/23/biocept-bioc-shares-gap-down-to-1-50.html.

Biocept Company Profile (NASDAQ:BIOC)

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Read More: NASDAQ Stock Market Explained

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.